ROLITETRACYCLINE

한글명:ROLITETRACYCLINE

카스 번호751-97-3

상품명:ROLITETRACYCLINE

CBNumberCB7666669

분자식C27H33N3O8

포뮬러 무게527.57

MOL 파일751-97-3.mol

화학적 성질

녹는점	163.5°C
끓는 점	608.16°C (rough estimate)
밀도	1.2902 (rough estimate)
굴절률	1.7120 (estimate)
저장 조건	-20°C Freezer, Under inert atmosphere
용해도	DMSO(약간 용해됨), 메탄올(매우 소량)
물리적 상태	고체
물리적 상태	단단한 모양
산도 계수 (pKa)	pKa 7.4 (Uncertain)
색상	매우 어두운 빨간색에서 매우 어두운 갈색까지
수용성	>20g/L(21ºC)

위험 및 안전 성명

위험품 표기

위험 카페고리 넘버

22-36/37/38

안전지침서

26-36

WGK 독일

RTECS 번호

QI9150000

NFPA 704:

	0
2		0

그림문자(GHS)

ROLITETRACYCLINE 화학적 특성, 용도, 생산

개요
Rolitetracycline was synthesized in 1958. Bristol-Myers Laboratories prepared it from tetracycline by introducing a pyrrolidinylmethyl moiety. This antibiotic is very soluble in water and more stable than tetracycline under acidic conditions. Rolitetracycline is used by intravenous injection, and its nitrate is used by both intravenous and intramuscular injections for therapy of the same infections as those treated by tetracycline.
용도
Rolitetracycline is a tetracycline antibiotic that may be given intravenously or intramuscularly in serious bacterial infections when oral administration is not practicable.
정의
ChEBI: A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.
일반 설명
Rolitetracycline, N-(pyrrolidinomethyl)tetracycline(Syntetrin), was introduced for use by intramuscular or intravenousinjection. This derivative is made by condensingtetracycline with pyrrolidine and formaldehyde in the presenceof tert-butyl alcohol. It is very soluble in water (1 g dissolvesin about 1 mL) and provides a means of injecting theantibiotic in a small volume of solution. It has been recommendedfor cases when the oral dosage forms are not suitable,but it is no longer widely used.
Pharmaceutical Applications
2-N-pyrrolidinomethyl-tetracycline. A semisynthetic derivative of tetracycline supplied as the nitrate sesquihydrate for parenteral use.
It is not absorbed from the gastrointestinal tract. It is highly soluble and therefore can be administered parenterally. Peak plasma concentrations of 4–6 mg/L occur at 0.5–1 h after 350 mg intravenously. The plasma elimination half-life is 5–8 h. About 50% of the dose is excreted in the urine, producing high concentrations.
Intravenous administration is occasionally accompanied by abnormal taste, shivering and rigors, hot flushes, facial reddening, dizziness and, rarely, circulatory collapse. Symptoms of myasthenia gravis have occasionally been exacerbated.

ROLITETRACYCLINE 공급 업체

ROLITETRACYCLINE 관련 검색

Send Inquriy